home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »


$48 million

Medical Device

ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock »

ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors »

ViewRay Announces $59 Million Equity Financing »

ViewRay Raises $50 Million through Sale of Common Stock »

ViewRay Announces $15.0 Million Capacity Expansion of its Term Loan Agreement »

ViewRay Receives FDA 510(k) Clearance for MRIdian Linac »

ViewRay Receives CE Mark Approval for its MRIdian Linac System »

ViewRay Announces $13.75 Million Private Placement »

ViewRay® Appoints Dr. Henry A. McKinnell, Jr. to its Board of Directors »

--Former Pfizer Chairman and CEO Brings Extensive Experience in Life Sciences and Public Companies--


CLEVELAND, April 12, 2016 — ViewRay, Inc. (Nasdaq: VRAY) announced today the appointment of Henry A. McKinnell, Jr., Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., to the company’s Board of Directors.


“We are delighted to welcome Hank McKinnell to the ViewRay Board of Directors,” said Chris A. Raanes, President and Chief Executive Officer of ViewRay. “Hank’s vast experience in medical innovation, in running a business, and in working with governments and other key stakeholders will be invaluable as we take ViewRay to the next level.”


“I am pleased to join ViewRay’s Board of Directors,” said Dr. McKinnell. “ViewRay’s innovative technology brings unprecedented visibility to radiation therapy, and can help countless cancer patients around the world.”


Dr. McKinnell retired as Chairman and CEO of Pfizer Inc. in 2006. His 35 years with the company included the positions of President of Pfizer Asia, President of Pfizer’s medical devices group, President of Pfizer Pharmaceuticals Group, and Chief Financial Officer.


Dr. McKinnell currently serves as the Chairman of the Board of Moody's Corporation and Chairman of the Board of the Accordia Global Health Foundation. His previous directorships include ExxonMobil Corporation, John Wiley & Sons, Optimer Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., and Angiotech Pharmaceuticals, Inc.


Previously, Dr McKinnell chaired the Business Roundtable, an association of Chief Executive Officers leading U.S. companies with $7 trillion in annual revenues, the Health Industry Manufacturers Association (now known as AdvaMed), the Pharmaceutical Research and Manufacturers of America, the Food and Drug Law Institute, Stanford University Graduate School of Business Advisory Council, and the Connecticut Science Center. Dr. McKinnell also served as Vice Chairman of the World Economic Forum.


Dr. McKinnell has received numerous awards, including the Grand Cordon of the Order of the Rising Sun, Japan's highest award other than to members of the Imperial Family and heads of state.


About ViewRay

ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.


ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


Michael Saracen
Senior Director, Marketing
ViewRay, Inc.
Phone: +1 408-242-2994
Email: media@viewray.com

ViewRay® Receives Regulatory Approval to Sell MRI-Guided Radiation Therapy System in Korea »

ViewRay® Completes Private Placement, Raises Aggregate of $29.4 Million »

ViewRay Completes Alternative Public Offering, Raises $26.7 Million »

ViewRay® Secures Up To $50M in Debt Financing From CRG »